Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1–11.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48:1560–1565.
   PubMed Web of Science ®Google Scholar
• Mahr A, Guillevin L, Poissonnet M, et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51:92–99.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Soowamber M, Baldwin C, et al. CAVALI: CAnadian VAsculitis learning initiative – second edition: an approach to vasculitis through interactive clinical cases. 2nd. Pagnoux C, editor. Toronto, Canada: CanVasc; 2019 June. 148.
   Google Scholar
• McGeoch L, Twilt M, Famorca L, et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol. 2016;43:97–120.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–317.
   PubMed Web of Science ®Google Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583–1594.
   PubMed Web of Science ®Google Scholar
• Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007 (Oxford);46:1615–1616.
   PubMed Web of Science ®Google Scholar
• Lapraik C, Watts R, Scott DG. Modern management of primary systemic vasculitis. Clin Med. 2007;7:43–47.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996 (Baltimore);75:17–28.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C. Therapeutic strategies for systemic necrotizing vasculitides. Allergol Int. 2007;56:105–111.
   PubMedGoogle Scholar
• Pagnoux C, FVSG. Vascularites nécrosantes systémiques – Protocole national de diagnostic et de soins. wwwhas-santefr 2009.
   Google Scholar
• Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488–494.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62:616–626.
   PubMed Web of Science ®Google Scholar
• Navon EP, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921–931.
   PubMed Web of Science ®Google Scholar
• Human A, Pagnoux C. Diagnosis and management of ADA2 deficient polyarteritis nodosa. Int J Rheum Dis. 2019;22(Suppl 1):69–77.
   PubMedGoogle Scholar
• Ombrello AK, Qin J, Hoffmann PM, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019;380:1582–1584.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Jarrousse B, et al. Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) . 1992;143:405–416.
   PubMedGoogle Scholar
• Guillevin L, Pagnoux C. When should immunosuppressants be prescribed to treat systemic vasculitides? Intern Med. 2003;42:313–317.
   PubMed Web of Science ®Google Scholar
• Ribi C, Cohen P, Pagnoux C, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62:1186–1197.
   PubMed Web of Science ®Google Scholar
• Puechal X, Pagnoux C, Baron G, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175–2186.
   PubMed Web of Science ®Google Scholar
• Collins MP, Periquet-Collins I. Nonsystemic vasculitic neuropathy: update on diagnosis, classification, pathogenesis, and treatment. Front Neurol Neurosci. 2009;26:26–66.
   PubMedGoogle Scholar
• Suppiah R, Hadden RD, Batra R, et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European vasculitis study group trials. Rheumatology (Oxford). 2011;50:2214–2222.
   PubMed Web of Science ®Google Scholar
• Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral nerve society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15:176–184.
   PubMed Web of Science ®Google Scholar
• Guillevin L. Treatment of polyarteritis nodosa and Churg-Strauss angiitis: indications of plasma exchange. Results of three prospective trials in 162 patients. The cooperative study group for the study of polyarteritis nodosa. Prog Clin Biol Res. 1990;337:309–317.
   PubMedGoogle Scholar
• Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49:93–100.
   PubMed Web of Science ®Google Scholar
• Samson M, Puechal X, Mouthon L, et al. Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clin Exp Rheumatol. 2017;35(Suppl 103):176–184.
   PubMedGoogle Scholar
• Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) (Baltimore). 1995;74:238–253.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C. Indication for plasma exchange for systemic necrotizing vasculidities. Transfus Apher Sci. 2007;36:179–185.
   PubMed Web of Science ®Google Scholar
• Zhu FH, Ang JY. The clinical diagnosis and management of Kawasaki disease: a review and update. Curr Infect Dis Rep. 2016;18:32.
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67:1738–1749.
   PubMed Web of Science ®Google Scholar
• Luca NJ, Yeung RS. Epidemiology and management of Kawasaki disease. Drugs. 2012;72:1029–1038.
   PubMed Web of Science ®Google Scholar
• McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927–e99.
   PubMed Web of Science ®Google Scholar
• de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology (Oxford). 2019;58:672–682.
   PubMed Web of Science ®Google Scholar
• Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev. 2010;9:441–448.
   PubMed Web of Science ®Google Scholar
• Dionne A, Burns JC, Dahdah N, et al. Treatment intensification in patients with kawasaki disease and coronary aneurysm at diagnosis. Pediatrics. 2019;143; pii: e20183341.
   Web of Science ®Google Scholar
• Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393:1128–1137.
   PubMed Web of Science ®Google Scholar
• Xue LJ, Wu R, Du GL, et al. Effect and safety of TNF inhibitors in immunoglobulin-resistant kawasaki disease: a meta-analysis. Clin Rev Allergy Immunol. 2017;52:389–400.
   PubMed Web of Science ®Google Scholar
• Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2016;3:122–133.
   PubMed Web of Science ®Google Scholar
• Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis. 2010;69:1934–1939.
   PubMed Web of Science ®Google Scholar
• Geetha D, Jin Q, Scott J, et al. Comparisons of guidelines and recommendations on managing antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2018;3:1039–1049.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. 2012;Suppl 2:139–274.
   Web of Science ®Google Scholar
• Souza AWS, Calich AL, Mariz HA, et al. Recommendations of the Brazilian society of rheumatology for the induction therapy of ANCA-associated vasculitis. Rev Bras Reumatol Engl Ed. 2017;57(Suppl 2):484–496.
   PubMedGoogle Scholar
• Wallace ZS, Lu N, Unizony S, et al. Improved survival in granulomatosis with polyangiitis: a general population-based study. Semin Arthritis Rheum. 2016;45:483–489.
   PubMed Web of Science ®Google Scholar
• Solans-Laque R, Rodriguez-Carballeira M, Rios-Blanco JJ, et al. Comparison of the birmingham vasculitis activity score and the five factors score to assess survival in anca-associated vasculitis. Arthritis Care Res (Hoboken). 2019 Apr. [Epub ahead of print]
   Google Scholar
• Puechal X, Pagnoux C, Perrodeau E, et al. Long-term outcomes among participants in the wegent trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol. 2016;68:690–701.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum. 2013;65:270–281.
   PubMed Web of Science ®Google Scholar
• Durel CA, Berthiller J, Caboni S, et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken). 2016;68:374–387.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40:2187–2198.
   PubMed Web of Science ®Google Scholar
• Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955–960.
   PubMed Web of Science ®Google Scholar
• Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5:e000905.
   PubMed Web of Science ®Google Scholar
• van Daalen EE, Rahmattulla C, Wolterbeek R, et al. Incidence of malignancy prior to antineutrophil cytoplasmic antibody-associated vasculitis compared to the general population. J Rheumatol. 2017;44:314–318.
   PubMed Web of Science ®Google Scholar
• Unizony S, Villarreal M, Miloslavsky EM, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75:1166–1169.
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Peh CA, et al. The effect of plasma exchange on end stage renal disease and death in patients with severe ANCA associated vasculitis. Nephrol Dial Transplant. 2018;33(abstract):LB01–2.
   Google Scholar
• Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013;14:73.
   PubMed Web of Science ®Google Scholar
• Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9–21.
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis. Curr Opin Rheumatol. 2018;30:388–394.
   PubMed Web of Science ®Google Scholar
• Kronbichler A, Kerschbaum J, Gopaluni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77:1440–1447.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28:2756–2767.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm. 2000;93:433–439.
   PubMed Web of Science ®Google Scholar
• Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–317.
   PubMed Web of Science ®Google Scholar
• Sakai R, Kondo T, Kikuchi J, et al. Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial. Mod Rheumatol. 2016;26:900–907.
   PubMed Web of Science ®Google Scholar
• Clinical trial of tocilizumab versus cyclophosphamide for microscopic polyangiitis and granulomatosis with polyangiitis [Internet]. 2018 cited 2018 Apr 17. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028278.
   Google Scholar
• de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461–2469.
   PubMed Web of Science ®Google Scholar
• Jones RB, Hiemstra TF, Ballarin J, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78:399–405.
   PubMed Web of Science ®Google Scholar
• Tuin J, Stassen PM, Bogdan DI, et al. Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial. Clin J Am Soc Nephrol. 2019;14(7):1021–1028.
   PubMed Web of Science ®Google Scholar
• Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. 2014;73:1376–1379.
   PubMed Web of Science ®Google Scholar
• Samson M, Puechal X, Devilliers H, et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. Autoimmun Rev. 2014;13:197–205.
   PubMed Web of Science ®Google Scholar
• Samson M, Puechal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–69.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790–2803.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304:2381–2388.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Metzler C, Tomlinson GA, et al. Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. Joint Bone Spine. 2014;81:337–341.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–1780.
   PubMed Web of Science ®Google Scholar
• Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3760–3769.
   PubMed Web of Science ®Google Scholar
• Gopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017;18:112.
   PubMed Web of Science ®Google Scholar
• Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143–1149.
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62: 1166–1173.
   PubMed Web of Science ®Google Scholar
• McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7:240–247.
   PubMed Web of Science ®Google Scholar
• Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1662–1668.
   PubMed Web of Science ®Google Scholar
• Jayne D, Blockmans D, Luqmani R, et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol. 2019;71:952–963.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921–1932.
   PubMed Web of Science ®Google Scholar
• Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155:341–343.
   PubMed Web of Science ®Google Scholar
• Pagnoux C. Churg-Strauss syndrome: evolving concepts. Discov Med. 2010;9:243–252.
   PubMed Web of Science ®Google Scholar
• Audemard-Verger A, Pillebout E, Guillevin L, et al. IgA vasculitis (Henoch-Shonlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14:579–585.
   PubMed Web of Science ®Google Scholar
• Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019 Mar. [Epub ahead of print]
   Web of Science ®Google Scholar
• Roman C, Dima B, Muyshont L, et al. Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature. Eur J Pediatr. 2019;178:1275–1281.
   PubMed Web of Science ®Google Scholar
• Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–1313.
   PubMed Web of Science ®Google Scholar
• Maritati F, Fenoglio R, Pillebout E, et al. Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schonlein). Arthritis Rheumatol. 2018;70:109–114.
   PubMed Web of Science ®Google Scholar
• Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57:775–788.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348–360.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med. 2015;128:950–955.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Corazza L, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford). 2014;53:2209–2213.
   PubMed Web of Science ®Google Scholar
• Haq SA, Pagnoux C. Infection-associated vasculitides. Int J Rheum Dis. 2019;22(Suppl 1):109–115.
   PubMedGoogle Scholar
• Ferri C, Ramos-Casals M, Zignego AL, et al. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145–1160.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology. 2017;153:49–52 e5.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Ramos-Casals M, Ferri C, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev. 2017;16:523–541.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis. Clin Gastroenterol Hepatol. 2019;17:518–526.
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Dal Maso L, Quartuccio L, et al. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Clin Exp Rheumatol. 2018;36(Suppl 111):107–114.
   PubMedGoogle Scholar
• Marson P, Monti G, Montani F, et al. Apheresis treatment of cryoglobulinemic vasculitis: a multicentre cohort study of 159 patients. Transfus Apher Sci. 2018;57:639–645.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–853.
   PubMed Web of Science ®Google Scholar
• Roccatello D, Sciascia S, Rossi D, et al. The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: a 10 years observation study. Oncotarget. 2017;8:52072–52077.
   PubMedGoogle Scholar
• Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res. 2010 (Hoboken);62:1787–1795.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Zuliani F, Corazza L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study. J Autoimmun. 2015;63:88–93.
   PubMed Web of Science ®Google Scholar
• Shah S, Jaggi K, Greenberg K, et al. Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Kidney J. 2017;10:470–474.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Springer J. Editorial: classifying antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides according to ANCA type or phenotypic diagnosis: salt or pepper? Arthritis Rheumatol. 2016;68:2837–2840.
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Lu N, Unizony S, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener’s): distinct patient subsets. Arthritis Rheumatol. 2016;68:2945–2952.
   PubMed Web of Science ®Google Scholar